Your session is about to expire
← Back to Search
Sphingosine 1-phosphate receptor modulator
Ozanimod for Pediatric Crohn's Disease
Phase 2 & 3
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial will study if ozanimod is effective, safe, and has desired drug levels and effects in children with Crohn's Disease.
Who is the study for?
This trial is for children with moderate to severe Crohn's Disease who haven't responded well to treatments like steroids, immunomodulators, biologics, or other immune therapies. They must have certain scores on disease activity and endoscopy scales. Kids with recent major bowel surgery or those needing it soon can't join.
What is being tested?
The study tests the effectiveness and safety of an oral medication called Ozanimod in young patients. It aims to see how the drug behaves in their bodies and its impact on Crohn's Disease symptoms.
What are the potential side effects?
Possible side effects of Ozanimod include headache, high blood pressure, liver enzyme changes, respiratory infections, flu-like symptoms, back pain and stomach-area (abdominal) pain.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2017 Phase 3 trial • 1320 Patients • NCT0204773449%
Influenza Like Illness
12%
Headache
11%
Nasopharyngitis
8%
Upper Respiratory Tract Infection
6%
Orthostatic Hypotension
6%
Pyrexia
5%
Alanine Aminotransferase Increased
4%
Urinary Tract Infection
3%
Hypertension
3%
Pharyngitis
2%
Gamma-Glutamyltransferase Increased
100%
80%
60%
40%
20%
0%
Study treatment Arm
Interferon Beta-1a
Ozanimod 0.5 mg
Ozanimod 1 mg
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Ozanimod Dose Level 2Experimental Treatment1 Intervention
Group II: Ozanimod Dose Level 1Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ozanimod
2018
Completed Phase 3
~4970
Find a Location
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,696 Previous Clinical Trials
4,099,066 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My Crohn's disease is active, with a PCDAI score of 30 or more and an endoscopy score of 6 or more.I have a stoma or similar condition that might need surgery or medical care soon.My doctor thinks I will need surgery to remove part of my intestines soon.I have Crohn's Disease and treatments like steroids or biologics haven’t worked well for me.I have had a major part of my small intestine removed or need nutrition through an IV.
Research Study Groups:
This trial has the following groups:- Group 1: Ozanimod Dose Level 1
- Group 2: Ozanimod Dose Level 2
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.